Jared S. Hopkins
Pharma Reporter at The Wall Street Journal
Pharma for @WSJ but I also once interviewed John Oates. [email protected] https://t.co/pMHJnBKbFF
Articles
-
1 week ago |
wsj.com | Jared S. Hopkins
Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration. The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry. President Trump said this week that he plans to announce pharma tariffs within two weeks.
-
2 weeks ago |
finance.yahoo.com | Jared S. Hopkins
Jared S. Hopkins Tue, Apr 29, 2025, 6:48 AM 3 min read In This Article: Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic. Pfizer forecast 2025 sales of between $61 billion and $64 billion and earnings per share of between $2.80 and $3, though it didn’t include any impact related to potential tariffs.
-
2 weeks ago |
wsj.com | Jared S. Hopkins
Delaware facility will ensure domestic supply of biologic drugs including cancer drug KeytrudaThe facility’s products will include biologic drugs and a new, easier-to-use version of Keytruda, the company’s blockbuster cancer drug. The plant marks Merck’s first in-house manufacturing site in the U.S. to make Keytruda, and will ensure American patients get the drug made domestically. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.
-
2 weeks ago |
wsj.com | Jared S. Hopkins
An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal)Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants. The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the threat of tariffs looms over the industry.
-
3 weeks ago |
jp.wsj.com | Jared S. Hopkins
米食品医薬品局（FDA）の大規模な人員削減を受け、難治性疾患やその他の疾患向け医薬品を開発するバイオテック企業が臨床試験や薬剤試験の延期を余儀なくされている。 業界関係者らによれば、FDAでは臨床試験の修正承認や医薬品承認プロセスの指導など、中核的機能に大幅な遅延が発生。これが医薬品開発の妨げとなっているという。またこれらの遅延により、医薬品の臨床試験完了と患者への提供までの時間が長期化し、新たな治療薬候補の試験資金も圧迫されていると関係者らは述べている。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8ウォール・ストリート・ジャーナル日本版今すぐ購読する Special Advertising Section アクセスランキング
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 6K
- Tweets
- 17K
- DMs Open
- Yes
Scoop: Drugmaker Mallinckrodt is talking to hedge funds that lent it money about a plan to file for bankruptcy and avoid paying $1 billion it owes to opioid victims https://t.co/FoczV33AER via @gladstonea @ajsaeedy
RT @eliotwb: 17 Weeks. I took a turn at writing some about Evan in today's print WSJ page devoted to him. check it out here Free Evan.…
Here is a link for the next 24 hours of @WSJ reporter Evan Gershkovich’s colleagues, family and friends reading his journalism - please tune in often to discover his work and share with the world #IStandWithEvan https://t.co/I6n9O5u1TS
